PMC

(P = 0.048, P = 0.020, respectively). +Sensored data, *P < 0.05, **P < 0.01. (B) The Flt23k nanoparticle plus triamcinolone group showed less total NV compared with the triamcinolone group (P = 0.000) and triamcinolone plus blank nanoparticle group (P = 0.028). The Flt23k nanoparticle plus triamcinolone group showed less graft NV compared with the triamcinolone group (P = 0.008). (C) The Flt23k nanoparticle plus triamcinolone group showed significantly less total lymphangiogenesis compared with the triamcinolone group (P = 0.043) and triamcinolone plus blank nanoparticle group (P = 0.014). The Flt23k nanoparticle plus triamcinolone group showed less graft lymphangiogenesis compared with the triamcinolone plus blank nanoparticle group (P = 0.028). (D) Representative images of NV (upper row) and lymphangiogenesis (lower row) in each group. (Adapted from Cho et al with permission from IOVS)

(A) The Flt23k nanoparticle plus triamcinolone group increased graft survival compared with the triamcinolone group and triamcinolone plus blank nanoparticle group (P = 0.048, P = 0.020, respectively). +Sensored data, *P < 0.05, **P < 0.01. (B) The Flt23k nanoparticle plus triamcinolone group showed less total neovascularization compared with triamcinolone group (P = 0.000) and triamcinolone plus blank nanoparticle group (P = 0.028). The Flt23k nanoparticle plus triamcinolone group showed less graft neovascularization compared with triamcinolone group (P = 0.008). (C) The Flt23k nanoparticle plus triamcinolone group showed significantly less total lymphangiogenesis compared with triamcinolone group (P = 0.043) and triamcinolone plus blank nanoparticle group (P = 0.014). The Flt23k nanoparticle plus triamcinolone group showed less graft lymphangiogenesis compared with the triamcinolone plus blank nanoparticle group (P = 0.028). (D) Representative pictures of neovascularization (upper row) and lymphangiogenesis (lower row) in each group.

 Triamcinolone acetonide measured by high pressure liquid chromatography. Trigon depot, triamcinolone acetonide concentration in the original resuspended Trigon ampule; 0.22 μm Millipore and 5 μm Pall, triamcinolone acetonide concentration after the corresponding filter techniques; Sed 0.5 ml and Sed 0.9 ml, triamcinolone acetonide concentration after the corresponding sedimentation technique and pellet reconstitution with 0.9 or 0.5 ml of BBS; Cent 1 ml, triamcinolone concentration after the corresponding centrifugation technique. Bars are means of three independent assays performed in duplicate. Errors bars represent standard deviations. *Triamcinolone acetonide concentration statistically significantly higher than Trigon depot, **Statistically significantly lower than Trigon depot (p<0.05).

Plasma triamcinolone acetonide concentrations over time after bilateral injection of TA-ER or TAcs. (a) Log-linear geometric mean (95% CI) baseline to day 43. (b) Linear-linear geometric mean (95% CI) baseline to day 43. (c) Log-linear geometric mean (95% CI) baseline to 24 h. (d) Linear-linear geometric mean (95% CI) baseline to 24 h.
CI, confidence interval; TA, triamcinolone acetonide; TAcs, triamcinolone acetonide crystalline suspension; TA-ER, triamcinolone acetonide extended-release.